目前常用的ＨＩＶ蛋白酶抑制剂主要有沙奎那韦、英地那韦、利托那韦和奈非那韦４ 种，它们对细胞色素Ｐ４５０（ＣＹＰ）系统中的ＣＹＰ３Ａ４酶均产生不同程度的抑制作用。尽管目前尚未从药代动力学研究和临床报告方面系统总结这些蛋白酶抑制剂与药物作用的专门资料，但ＨＩＶ感染者常用的许多药物都可能与它们发生相互作用。本文总结了已发表的相关文献，着重强调ＨＩＶ蛋白酶抑制剂与药物相互作用的强度及临床用药的建议。 The most commonly used HIV protease inhibitors are saquinavir, indinavir, ritonavir, and nelfinavir, which all inhibit the CYP3A4 enzyme in the cytochrome P450 (CYP) system to varying degrees effect. Although no specific information on these protease inhibitors and drug effects has been systematically summarized in pharmacokinetic studies and clinical reports, many drugs commonly used by HIV-infected people may interact with them. This article summarizes published literature that highlights the strength of HIV protease inhibitors and drug interactions and recommendations for clinical use.